Healthpeak Properties, Inc.

▲ Bull Case

• ◆Lab occupancy inflects to 83%+ in FY2027 as biotech VC recovery ($7.5B/Q in Q1 2026, above 2-year average) translates into demand with a 12-month lag, combined with a 26% contraction in the construction pipeline. FFO reaches $2.00/share; multiple re-rates to 13x; price target $26 (+33%); total return +43.4%.
• ◆SOTP gap closes as Janus Living stake ($5.6B, 41% of market cap) is increasingly credited by the market. At market value, the MOB/Lab core is priced at only 6.7x FFO vs. 12–14x for pure-MOB peers — a gap that should compress as Janus grows (Q1 2026: revenue +35%, EBITDA +42%) and lab recovery materializes, potentially unlocking $5–8/share of embedded value.
• ◆MOB segment continues to compound at 3–4%/yr SS NOI growth with re-leasing spreads of +5.8% cash, supporting a 6.26%+ dividend yield through the trough. Treasury rates declining below 4% would further re-rate the multiple on this defensive, IG-tenant-anchored income stream, providing a durable floor and incremental upside independent of lab recovery timing.

▼ Bear Case

• ◆Lab occupancy extends to 73–75% with no near-term re-rating catalyst. Biotech VC recovery fails to translate into incremental leasing demand at DOC's Boston/SF locations; the ARE dividend cut has created lasting sector-wide risk aversion to life science REITs. FFO falls to $1.65; multiple stays at 10x; price target $17 (−13%); total return −2.8% (barely negative as dividend nearly covers).
• ◆Net Debt/EBITDA rises above 8.5x due to EBITDA pressure or a poorly-timed acquisition, triggering IG credit downgrade risk on the $8.5B debt stack, eliminating acquisition capacity, and freezing dividend growth. The $650M refinancing headwind (exact rate and net FFO impact unconfirmed due to transcript unavailability) could be materially worse than modeled.
• ◆Janus Living (NYSE: JAN) declines 35%+ as senior housing fundamentals deteriorate, reducing DOC's SOTP-implied value by ~$2.70/share and eliminating the margin of safety at current prices. Simultaneously, if MOB SS NOI growth decelerates below 2% for multiple quarters due to e-health substitution or tenant consolidation, the income floor narrative erodes, compressing the multiple further toward severe-case levels of $12–15.

“The central debate is whether DOC's life science overhang is a temporary trough or a structural multiple suppressor. Bears argue that the ARE dividend cut (45% in 2025) permanently reprices life science REITs, that 30%+ market vacancy in Boston/SF will take 3–5 years to absorb (not 12–18 months), and that DOC's 7.5x leverage leaves limited margin for error. Bulls counter that DOC's 55% MOB exposure provides a structural floor ARE lacked, that VC recovery in Q1 2026 historically leads occupancy inflection by 12–18 months, and that the Janus stake creates a massive SOTP discount (6.7x implied FFO on core vs. 12–14x peers) that will eventually close. The consensus appears to be pricing the lab overhang as semi-permanent (11.3x vs. 12–14x sector), and the key unresolved question is whether Q2/Q3 2026 lab occupancy data confirms a Q/Q inflection — which would be the single most important catalyst for re-rating. Transcript unavailability means management's specific market-by-market lab guidance (Boston, SF, San Diego separately) and their $650M refinancing impact disclosure remain unverified.”

• ◆Q2 2026 lab occupancy Q/Q inflection (even +0.5pp positive change confirms biotech VC → demand lag thesis)
• ◆Biotech VC funding sustaining above $7B/quarter through H2 2026, validating 12–18 month demand conversion timeline
• ◆Construction pipeline contraction (26% in 2026) tightening effective supply in Boston/Kendall Square and South SF markets
• ◆Janus Living (NYSE: JAN) continued strong growth (Q1 2026: revenue +35%, EBITDA +42%) increasing stake value and SOTP discount awareness
• ◆10-year Treasury declining below 4.0%, re-rating defensive REIT multiples broadly and reducing DOC's cost of capital
• ◆Potential Janus Living stake monetization or strategic transaction clarifying embedded value for DOC shareholders

• ◆Lab occupancy falls below 70% for two consecutive quarters — bear case becomes base case; FFO trajectory to $1.87 FY2027E is broken
• ◆Dividend cut or suspension — invalidates the primary income thesis; would reprice stock toward $12–15
• ◆Net Debt/EBITDA rises above 8.5x — IG credit downgrade risk on $8.5B debt stack; acquisition capacity eliminated
• ◆Janus Living (NYSE: JAN) declines 35%+ in 6 months — $1.9B stake value loss eliminates PWFV margin of safety
• ◆MOB SS NOI growth falls below 2% for three consecutive quarters — income floor narrative erodes; multiple compresses
• ◆$650M refinancing headwind materially worse than modeled (exact rate unconfirmed; transcript unavailable)
• ◆Biotech VC funding reversal in H2 2026 extending the lab recovery timeline by 12–24 months beyond current base case